Literature DB >> 32811645

Neferine sensitized Taxol-resistant nasopharygeal carcinoma to Taxol by inhibiting EMT via downregulating miR-130b-5p.

Xianyao Wang1, Kai Wang1, Jian Xiao1, Yexun Song2, Heqing Li3.   

Abstract

Taxol resistance led to the poor survival prognosis in advanced nasopharyngeal carcinoma (NPC). Epithelial-mesenchymal transition (EMT) plays an important role in tumor chemoresistance. Neferine (NEF) is found to sensitize the cancer cells to chemotherapeutic agents, but its effects and mechanisms on NPC Taxol resistance is unclear. In this study, we discovered that Taxol-resistant cell lines 5-8F/Taxol and CNE-1/Taxol had the greater ability to metastasis and the higher expression of EMT markers. Then we found that NEF could inhibit the viability and EMT process in the Taxol-resistant cell lines. Furthermore, we confirmed that NEF could augment therapeutic efficacy of Taxol on NPC Taxol-resistant cell lines. Further through Microarray based analysis, we found that miR-130b-5p was stably down-regulated after treating 5-8F/Taxol with NEF. Later we verified that up-regulation of miR-130b-5p could not only promote the EMT-related migration/invasion, but also impair the inhibition effects of NEF on the EMT-associated metastatic ability and the chemotherapy resistance to Taxol. In conclusion, our results firstly suggested that NEF may enhanced Taxol sensitivity in NPC Taxol-resistant cell lines through inhibition of EMT which mediated by miR-130b-5p downregulation in vitro and in vivo. NEF may be used as a Taxol sensitizer in chemotherapy of NPC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EMT; Nasopharyngeal carcinoma; Neferine; Taxol resistance; microRNA

Year:  2020        PMID: 32811645     DOI: 10.1016/j.bbrc.2020.08.008

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Noncoding RNA actions through IGFs and IGF binding proteins in cancer.

Authors:  Aidan Kerr; Robert C Baxter
Journal:  Oncogene       Date:  2022-05-21       Impact factor: 8.756

Review 2.  Research progress of nanocarriers for gene therapy targeting abnormal glucose and lipid metabolism in tumors.

Authors:  Xianhu Zeng; Zhipeng Li; Chunrong Zhu; Lisa Xu; Yong Sun; Shangcong Han
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

3.  Identification of KIF4A and its effect on the progression of lung adenocarcinoma based on the bioinformatics analysis.

Authors:  Yexun Song; Wenfang Tang; Hui Li
Journal:  Biosci Rep       Date:  2021-01-29       Impact factor: 3.840

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.